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ABSTRACT
Objective: Alpha-mangostin (α-MG) has been shown to possess antifibrotic effects. However, the specific mechanism of action of this compound 
remains poorly understood. Therefore, the aim of this study was to investigate the effect of α-MG on the expression levels of transforming growth 
factor (TGF)-β1 and matrix metalloproteinase-3 (MMP3) in hepatic stellate cells (HSCs) induced by TGF-β.
Methods: Immortalized HSCs and LX-2 cells were incubated with TGF-β with or without α-MG (5 and 10 μM). The viability of LX-2 cells was assessed 
using the Trypan Blue Exclusion Method. The effect of α-MG on cell morphology and the mRNA expression levels of TGF-β1, TGF-β receptor, and MMP3 
was then evaluated.
Results: TGF-β enhanced the proliferation of HSCs and caused significant increases in the expression levels of TGF-β1, TGF-β receptor, and MMP3. 
α-MG treatment reduced the proliferation of HSCs and decreased the expression levels of TGF-β1, TGF-β1 receptor, and MMP3.
Conclusion: α-MG is a potential antifibrotic agent due to its antiproliferative and antifibrogenic effects, mainly by suppressing the expression of TGF-β 
and MMP3 on the surfaces of activated HSCs.
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INTRODUCTION
Hepatic stellate cells (HSCs) are liver-specific mesenchymal cells 
that play a role in the pathogenesis of liver fibrosis [1,2]. HSCs are 
located in the perisinusoidal space and contain lipid droplets rich in 
Vitamin A. In the normal liver, stellate cells remain quiescent and play a 
role in maintaining the basal balance of the matrix membrane [2,3]. In 
response to liver injury, these cells receive signals from a wide variety of 
growth factors, cytokines, lipid mediators, and adipokines to promote 
survival at the sites of liver injury containing damaged hepatocytes and 
immune cells. HSCs then transdifferentiate to activated myofibroblast-
like cells [2].
Transforming growth factor-β (TGF-β) is a key profibrogenic mediator 
that plays a major role in the activation of HSCs. Activated HSCs then 
secrete TGF-β in autocrine- and paracrine-dependent manners to 
mediate the production, degradation, and accumulation of molecules 
in the extracellular matrix (ECM) [1,4–6]. In humans, TGF-β exists in 
three homologous isoforms: TGF-β1, TGF-β2, and TGF-β3. On binding 
to TGF-β receptor type II, TGF-β consecutively recruits TGF-β receptor 
type I to the complex and initiates TGF-β signaling, which causes the 
activation of SMAD-dependent and SMAD-independent pathways [7,8].
Activated HSCs express many ECM-associated proteins, including 
collagen type I, α-smooth muscle actin, matrix metalloproteinases 
(MMPs), and tissue inhibitors of metalloproteinases (TIMPs) [4,9]. 
Accumulation of these proteins by the ECM without sufficient 
degradation will form deposits that destroy and distort the normal 
hepatic structure, which results in cirrhosis and liver failure [1,2,6,8,10]. 
ECM degradation is mediated by MMPs, a family of zinc-dependent 
enzymes grouped into collagenases, gelatinases, stromelysins, and 
membrane-type MMPs. TIMPs regulate the MMP activity by binding to 
MMPs, thereby inhibiting proteolytic activities [11].
Although the TGF-β pathway is important in the pathogenesis of liver 
fibrosis, few targeted drugs have been developed. Pirfenidone, a pyridine 
derivate, is the only drug currently available to specifically block TGF-β1 
production for the long-term improvement of liver inflammation and 
fibrosis [9]. In addition, sorafenib is the only drug approved for the 
treatment of advanced-stage hepatocellular carcinoma. Hence, the 
development of new drugs and therapeutic regimens is an immediate 
medical necessity [12].
Various herbal products have been shown anti-liver fibrogenic 
activities by blocking TGF-β signaling and HSC activation [13]. For 
example, alpha-mangostin (α-MG), a xanthone derivate, is a major 
bioactive compound found in the tropical fruit Garcinia mangostana 
Linn. that has antifibrotic and antiproliferative activities, and has 
been shown to decrease TGF-β levels. However, the mechanism of 
action of this compound remains poorly understood. Therefore, the 
aim of the present study was to evaluate the effect of α-MG on the 




Immortalized human HSCs and LX-2 cells were cultured as described 
elsewhere [3].
Cell treatments
Cells were treated with one of four regimens in 10-cm culture dishes: 
(1) Medium only; (2) TGF-β at 2 ng/mL for 24 h, then new medium 
with TGF-β at 2 ng/mL for 24 h; (3) TGF-β at 2 ng/mL for 24 h, then 
new medium with TGF-β at 2 ng/mL and α-MG at 5 µM for 24 h; or 
(4) TGF-β at 2 ng/mL for 24 h, then new medium with TGF-β at 2 ng/mL 
and α-MG at 10 µM for 24 h. Afterward, the cells were harvested using 
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trypsin+ethylenediaminetetraacetic acid and subjected to cell viability 
analysis and RNA isolation. All experiments were performed 3 times in 
duplicate.
Cell viability analysis
Cell viability was assessed using the trypan blue exclusion assay and 
presented as the percentage of proliferating cells.
Quantitative reverse transcriptase-polymerase chain reaction
RNA was isolated from cells using the High Pure RNA Isolation Kit 
(Roche Applied Science, Penzberg, Germany) and further synthesized 
to complementary DNA (cDNA) using the Transcriptor First Strand 
cDNA Synthesis Kit (Roche Applied Science). mRNA analyses of TGF-β, 
TGF-β receptor, and MMP3 were performed using a LightCycler® 
480 Instrument (Roche Applied Science) with FastStart Essential 
DNA Green Master mix (Roche Life Sciences) in accordance with the 
manufacturer’s protocol. The number of quantification cycles (Cq) was 
calculated automatically using the machine’s software. Cq data were 
processed using the Livak method to determine the expression levels. 
Beta-actin was used as a housekeeping gene.
The following primer sequences were used in this study: TGF-β (F): 
5’-TGA ACC GGC CTT TCC TGC TTC TAC ATG-3’; TGF-β (R): 5’-GCG GAA 
GTC AAT GTA CAG CTG CCG C-3’; TGF-β1 receptor (F): 5’-TTG CTG GAC 
CAG TGT GCT TCG-3’; TGF-β1 receptor (R): 5’-CCA TCT GTT TGG GAT 
ATT TGG CC-3’; MMP3 (F): 5’-CAA AAC ATA TTT CTT TGT AGA GGA 
CAA-3’; MMP3 (R): 5’-TTC AGC TAT TTG CTT GGG AA-3’; β-actin (F): 
5’-GCT GGA AGG TGG ACA GCG A-3’; and β-actin (R): 5’-GGC ATC GTG 
ATG GAC TCC G-3’.
Statistical analysis
The results are presented as the mean±standard error of the mean. 
One-way analysis of variance followed by the Tukey test was used for 
multiple comparisons. A probability p>0.05 was considered statistically 
significant. All statistical analyses were performed using GraphPad 
Prism 7.0d software (GraphPad Software, Inc., La Jolla, CA, USA).
RESULTS
There was no change in the morphology of LX-2 cells after 48 h of 
treatment with TGF-β with or without α-MG as observed under an 
inverted microscope at 10× magnification (Fig. 1).
The addition of TGF-β increased cell viability by 2-fold, as compared to 
untreated cells. Treatment with α-MG at the lower dose (5 µM) failed 
to reverse cell viability, whereas the higher dose of α-MG reversed cell 
viability back to normal (Fig. 2).
The addition of TGF-β to the cell medium caused a significant increase 
in the mRNA expression levels of TGF-β1 and its receptor. However, 
the increase in the mRNA expression of the TGF-β1 receptor was not 
as great as that of TGF-β1 (Fig. 3). The addition of α-MG decreased the 
mRNA expression of TGF-β1 and strongly decreased that of the TGF-β 
receptor (Fig. 3).
The mRNA expression levels of MMP3 were significantly elevated by the 
treatment of TGF-β and reversed back to normal with α-MG at 10 µM, 
but not at 5 µM (Fig. 4).
DISCUSSION
HSCs are the main source of the ECM and important for the 
development of hepatic fibrosis. LX-2 cells are a human HSC line that 
is often used to study liver diseases. TGF-β treatment of LX-2 cells in 
this study was used as an in vitro model of hepatic fibrosis. TGF-β is 
a pleiotropic fibrogenic factor that is involved in a wide spectrum of 
cellular process, including differentiation, proliferation, apoptosis, and 
migration [6,15]. As is widely known, TGF-β can induce epithelial–
mesenchymal transition (EMT) of cultured hepatocytes including 
HSCs. High levels of TGF-β as consequence of liver injury activate 
HSCs and promote myofibroblast transdifferentiation as key effector 
cells in the fibrotic state [8,12,16–18]. Ho et al. used TGF-β at different 
concentrations to explore the short-term (3 days) effects on activated 
hepatocytes. In line with the results of the present study, they found no 
apparent morphological changes from a low treatment dose (0.2 ng/
mL) for 3 days until 2 weeks or with a high dose (10 ng/mL) for 3 days. 
However, short-term treatment with TGF-β at 0.2 and 0.5 ng/mL 
upregulated the mRNA expression of EMT-related genes. In this study, 
there was no morphological differentiation between LX-2 cells after 
treatment with TGF-β with or without α-MG. This finding suggests 
that TGF-β treatment at 2 ng/mL for 24 h was not sufficient to induce 
morphological changes of HSCs [5]. However, further studies are 
needed to monitor EMT markers, such as vimentin and E-cadherin, 
to conclude that short-term (24 h) treatment with TGF-β at 2 ng/mL 
failed to induce EMT.
In contrast to the present study, Park et al. reported the transition of 
HSCs to spindle-like mesenchymal cells after treatment with TGF-β1 
for 12 h and these changes became even more evident after 48 h. 
Fig. 2: Percentage of viable cells versus control cells after 
treatment with medium only (untreated cells), TGF-β (2 ng), 
TGF-β (2 ng)+α-MG (5 µM), or TGF-β (2 ng)+α-MG (10 µM). 
*p<0.05 versus control (no treatment); #p<0.05 versus TGF-β
Fig. 1: Morphology of LX-2 cells after treatment with (a) medium 
only (untreated cells), (b) TGF-β at 2 ng/mL, (c) TGF-β at 2 ng/mL 
+α-MG at 5 µM, or (d) TGF-β at 2 ng/mL+α-MG at 10 µM. 
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This finding was supported by the downregulation of E-cadherin and 
upregulation of vimentin, as markers of the EMT process [8,19,20].
The results of the present study demonstrated that TGF-β treatment 
increased the number of viable cells by 2-fold as compared to untreated 
control cells. This increase in proliferation may due to TGF-β/SMAD-
independent signaling, as the PI3K/Akt pathway can enhance Akt 
phosphorylation and increase HSC proliferation. A study by Zang et al. 
showed that TGF-β treatment increased the expression level of the 
proliferation marker Ki-67 in rabbit cornea cells, and Kang et al. found 
that TGF-β1 treatment at 2 ng/mL at 24 and 48 h enhanced the HSC 
proliferation, whereas α-MG at 10 μM suppressed this proliferation 
back to normal, which suggested the inhibitory activity of this substance 
against HSC proliferation [3,6].
In the healthy liver, high TGF-β1 expression is only found in endothelial 
sinusoidal and Kupffer cells. On activation, HSCs modify the transcription 
of some key genes including α-smooth muscle actin, type 1 collagen, 
MMP-2, TGF-β1, TGF-β receptor, and TIMP-1 and TIMP-2. Recent studies 
have found that the expression levels of signal transducer and activator 
of transcription 3 (Stat3) and TGF-β were increased in patients with 
advanced fibrosis [13,20]. Kim et al. reported an increase in the relative 
expression of TGF-β1 after treatment with TGF-β1 (2 ng/mL) for 12 h 
in HSC-T6 cells, an immortalized rat HSC cell line [21]. These findings 
explain the increased expression of TGF-β1 and TGF-β receptors after 
treatment with TGF-β.
As reported previously, TGF-β1 activates HSCs and the activated HSCs 
synthesize and secrete ECM-degrading enzymes, known as MMPs, and 
their inhibitors, TIMPS. In the early phase, HSCs produce MMPs, which 
degrade the normal ECM in the liver. Afterward, fully activated HSCs 
suppress the expression of MMPs and promote that of TIMPs as natural 
inhibitors of MMPs [2,19]. The expression levels of MMP3 and TIMP-1 
are upregulated during liver fibrosis. Kang et al. found that TGF-β1 
stimulation decreased MMP-2 expression in human prostate carcinoma 
cells, whereas the addition of α-MG decreased the expression levels of 
MMP2, MMP9, and urokinase plasminogen activator [6,22].
CONCLUSION
TGF-β acts as a gateway in intracellular signaling. Thus, there is a need 
to develop drugs to inhibit the intracellular activity of TGF-β. The results 
of this study confirmed that α-MG not only inhibited the proliferation 
of HSCs but was also an effective marker of fibrogenesis through the 
TGF-β pathway. Therefore, α-MG should be further investigated as a 
potential target for the treatment of liver fibrosis.
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